Palvella Therapeutics, Inc. (PVLA)
| Market Cap | 133.65M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -7.75M |
| Shares Out | 11.22M |
| EPS (ttm) | -1.36 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 19,948 |
| Open | 11.17 |
| Previous Close | 12.00 |
| Day's Range | 11.17 - 11.96 |
| 52-Week Range | 6.20 - 22.32 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 38.00 (+219.06%) |
| Earnings Date | Feb 15, 2025 |
About PVLA
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. Its lead product candidate is QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is bas... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for PVLA stock is "Strong Buy" and the 12-month stock price forecast is $38.0.
News
Palvella Therapeutics Announces Closing of Merger with Pieris Pharmaceuticals and Concurrent Private Placement of $78.9 Million
Palvella Therapeutics to debut on Nasdaq under the ticker symbol “PVLA” as a publicly traded rare disease biopharmaceutical company advancing a late clinical-stage pipeline and a platform for treating...